Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Update August 2021

Grössmann, N. (2021): Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Update August 2021. Oncology Fact Sheet Nr. 42.

[thumbnail of Oncology Fact Sheet Nr.42_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
107kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WJ Urogenital system > WJ 300-378 Kidney
Language:	English
Series Name:	Oncology Fact Sheet Nr. 42
Deposited on:	24 Mar 2021 16:52
Last Modified:	05 Aug 2021 10:37

Repository Staff Only: item control page